blfs-20260806

BioLife Solutions Reports Second Quarter 2026 Financial Results

Total revenue of $28.5 million, up 21% over Q2 2025

GAAP gross margin of 64% and non-GAAP adjusted gross margin of 65%

GAAP net income of $45.1 million, inclusive of a $42.4 million non-cash income tax benefit, and non-GAAP adjusted EBITDA of $7.4 million, or 26% of revenue

Repligen to acquire BioLife and the proposed transaction is expected to close in the fourth quarter of 2026

BOTHELL, Wash. (August 6, 2026) – BioLife Solutions, Inc. (Nasdaq: BLFS) (“BioLife” or the “Company”), a leading developer and supplier of cell processing tools and services for the cell and gene therapy (“CGT”) market, announces financial results for the three and six months ended June 30, 2026.

“We delivered another strong quarter, with solid execution across the business led by our market-leading biopreservation media franchise,” said Roderick de Greef, Chairman and Chief Executive Officer of BioLife. “This continued performance underscores the important role our technologies play in enabling the advancement of cell and gene therapies. We look forward to building on this foundation through our announced combination with Repligen, which is expected to close in the fourth quarter of 2026.”

Second Quarter 2026 Business Highlights

•On July 21, 2026, BioLife entered into a definitive agreement under which Repligen, subject to customary closing conditions, will acquire BioLife for a total enterprise value of approximately $1.5 billion, comprised of $11.25 cash and 0.1442 shares of Repligen’s common stock, on a per share basis of BioLife’s common stock. As a result of the merger, BioLife will cease to be a publicly traded company. The transaction is expected to close in the fourth quarter of 2026, subject to approval by BioLife stockholders, regulatory approvals and other customary closing conditions.

•Our biopreservation media is utilized in approximately 250 ongoing commercially sponsored clinical trials in the U.S., representing a more than 70% market share. This includes over 30 Phase III trials, or nearly 80% of these late-stage trials. Our CellSeal vials and hPL products are used in over 35 clinical trials.

•Our biopreservation media is embedded in 18 unique commercial CGTs as of June 30, 2026, with expectations that approvals for 8 additional products, geographic expansions, earlier lines of treatment, or new indications will occur over the next 12 months. Our CellSeal cryogenic vials and hPL products are embedded in four approved therapies.

Second Quarter 2026 Financial Results

BioLife is presenting various financial metrics under U.S. generally accepted accounting principles (GAAP) and as adjusted (non-GAAP). In addition, BioLife completed the divestiture of evo in 2025, and is presenting its financial condition and operating results as discontinued operations for all periods presented within the Unaudited Condensed Consolidated Balance


			Page 1

Sheets and Unaudited Condensed Consolidated Statements of Operations. The Unaudited Condensed Consolidated Statements of Comprehensive Income (Loss) and Unaudited Condensed Consolidated Statements of Cash Flows are presented on a consolidated basis for both continuing operations and discontinued operations. All amounts, percentages, and disclosures for all periods presented reflect only the continuing operations of the Company unless otherwise noted.

REVENUE

•Total revenue for the second quarter of 2026 was $28.5 million, an increase of $5.0 million, or 21%, from $23.4 million for the second quarter of 2025 and up $1.0 million, or 4%, from the first quarter of 2026.

•Total revenue for the six months ended June 30, 2026 was $56.0 million, an increase of $10.5 million, or 23%, from $45.5 million for the six months ended June 30, 2025.

GROSS MARGIN

•Gross margin (GAAP) for the second quarter of 2026 was 64% compared with 65% for the second quarter of 2025. Adjusted gross margin (non-GAAP) for the second quarter of 2026 was 65% compared with 66% for the second quarter of 2025.

•Gross margin (GAAP) for the six months ended June 30, 2026 was 64% compared with 66% for the six months ended June 30, 2025. Adjusted gross margin (non-GAAP) for the six months ended June 30, 2026 was 65% compared with 67% for the six months ended June 30, 2025.

OPERATING INCOME / (LOSS)

•Operating income (GAAP) for the second quarter of 2026 was $1.7 million compared with an operating loss of $16.1 million for the second quarter of 2025. Adjusted operating income (non-GAAP) for the second quarter of 2026 was $3.1 million compared with an adjusted operating loss of $0.3 million for the second quarter of 2025.

•Operating income (GAAP) for the six months ended June 30, 2026 was $1.7 million compared with an operating loss of $16.6 million for the six months ended June 30, 2025. Adjusted operating income (non-GAAP) for the six months ended June 30, 2026 was $4.1 million compared with $0.9 million for the six months ended June 30, 2025.

NET INCOME / (LOSS)

•Net income (GAAP) for the second quarter of 2026 was $45.1 million compared with a net loss of $15.3 million for the second quarter of 2025. Adjusted net income (non-GAAP) for the second quarter of 2026 was $4.2 million compared with $0.6 million for the second quarter of 2025. Due to the release of our valuation allowance during the second quarter of 2026, we recognized a non-cash income tax benefit of $42.4 million.


			Page 2

•Net income (GAAP) for the six months ended June 30, 2026 was $46.3 million compared with a net loss of $15.1 million for the six months ended June 30, 2025. Adjusted net income (non-GAAP) for the six months ended June 30, 2026 was $6.3 million compared with $2.6 million for the six months ended June 30, 2025.

NET INCOME / (LOSS) PER SHARE

•Net income per share (GAAP) for the second quarter of 2026 was $0.92 compared with net loss per share of $0.32 for the second quarter of 2025. The release of our valuation allowance during the second quarter of 2026 had an $0.87 impact on our net income per share.

•Net income per share (GAAP) for the six months ended June 30, 2026 was $0.95 compared with net loss per share of $0.31 for the six months ended June 30, 2025. The release of our valuation allowance during the six months ended June 30, 2026 had an $0.87 impact on our income per share.

ADJUSTED EBITDA

•Adjusted EBITDA, a non-GAAP measure, for the second quarter of 2026 was $7.4 million, or 26% of revenue, compared with $5.6 million, or 24% of revenue, for the second quarter of 2025.

•Adjusted EBITDA, a non-GAAP measure, for the six months ended June 30, 2026 was $13.5 million, or 24% of revenue, compared with $11.0 million, or 24% of revenue, for the six months ended June 30, 2025.

CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES

•Cash, cash equivalents, and marketable securities as of June 30, 2026 were $113.1 million.

(As a result of presenting amounts in millions, rounding differences may exist in the percentages above.)

Conference Call & Webcast

Due to the pending acquisition of BioLife by Repligen, BioLife will not be hosting a conference call.

About BioLife Solutions

BioLife is a leading developer and supplier of cell processing tools and services for the CGT market. Our expertise facilitates the commercialization of new therapies by supplying solutions that maintain the health and function of biologic materials during the collection, development,


			Page 3

manufacturing and distribution. For more information, please visit www.biolifesolutions.com, and follow BioLife on LinkedIn and X.

Cautions Regarding Forward Looking Statements

Certain statements contained in this press release are not historical facts and may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “plans,” “expects,” “believes,” “anticipates,” “designed,” “may,” “estimate,” “guidance,” and similar words are intended to identify forward-looking statements. Forward-looking statements are based on our current expectations and beliefs, and involve a number of risks and uncertainties that are difficult to predict and that could cause actual results to differ materially from those stated or implied by the forward-looking statements. A description of certain of these risks, uncertainties and other matters can be found in filings we make with the U.S. Securities and Exchange Commission, all of which are available at www.sec.gov. Because forward-looking statements involve risks and uncertainties, actual results and events may differ materially from results and events currently expected by us. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. We undertake no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in its expectations with regard to these forward-looking statements or the occurrence of unanticipated events.

Non-GAAP Measures of Financial Performance

To supplement our financial statements, which are presented on the basis of U.S. generally accepted accounting principles (GAAP), the following non-GAAP measures of financial performance are included on a consolidated basis in this release: adjusted gross margin, adjusted operating expenses, adjusted operating income/(loss), adjusted net income/(loss), earnings before interest, taxes, depreciation and amortization (EBITDA), and adjusted EBITDA. A reconciliation of GAAP to adjusted non-GAAP financial measures is included as an attachment to this press release.

We believe these non-GAAP financial measures are useful to investors in assessing our operating performance. We use these financial measures internally to evaluate our operating performance and for planning and forecasting of future periods. We also believe it is in the best interests of investors to provide this non-GAAP information.

While we believe these non-GAAP financial measures provide useful supplemental information to investors, there are limitations associated with the use of these non-GAAP financial measures. These non-GAAP financial measures may not be reported by competitors, and they may not be directly comparable to similarly titled measures of other companies due to differences in calculation methodologies. The non-GAAP financial measures are not an alternative to GAAP information and are not meant to be considered in isolation or as a substitute for comparable GAAP financial measures. They should be used only as a supplement to GAAP information and should be considered only in conjunction with our consolidated financial statements prepared in accordance with GAAP.


			Page 4

Media & Investor Relations

At the Company

Troy Wichterman

Chief Financial Officer

(425) 402-1400

[email protected]

John Graziano

Investor Relations

[email protected]

Investors

Alliance Advisors IR

Vivian Cervantes

(973) 873-7724

[email protected]


			Page 5

BIOLIFE SOLUTIONS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited, amounts in thousands, except share and per share amounts)


	Three Months Ended June 30,				Six Months Ended June 30,
(In thousands, except per share and share data)	2026		2025		2026		2025

Revenue	$	28,466	$	23,438	$	55,966	$	45,492
Cost of revenue	10,179		8,203		20,182		15,457
Gross profit	18,287		15,235		35,784		30,035
Operating expenses:
General and administrative	10,694		11,232		22,901		22,582
Sales and marketing	2,782		2,577		5,308		5,020
Research and development	2,958		1,965		5,608		3,404
IPR&D expense	—		15,521		—		15,521
Intangible asset amortization	157		66		242		132
Total operating expenses	16,591		31,361		34,059		46,659
Operating income (loss)	1,696		(16,126)		1,725		(16,624)

Other income:
Interest income, net	994		684		2,035		1,365
Other income	63		247		242		349

Total other income, net	1,057		931		2,277		1,714

Income (loss) before income tax (benefit) expense	2,753		(15,195)		4,002		(14,910)
Income tax (benefit) expense	(42,351)		126		(42,288)		140
Net income (loss) from continuing operations	$	45,104	$	(15,321)	$	46,290	$	(15,050)

Discontinued operations:
Loss from discontinued operations before income tax expense	—		(517)		—		(1,236)
Income tax benefit	—		—		—		—
Loss from discontinued operations	$	—	$	(517)	$	—	$	(1,236)

Net income (loss)	$	45,104	$	(15,838)	$	46,290	$	(16,286)

Earnings (loss) per share - Basic:
Continuing operations	$	0.92	$	(0.32)	$	0.95	$	(0.31)
Discontinued operations	$	—	$	(0.01)	$	—	$	(0.03)
Net income (loss)	$	0.92	$	(0.33)	$	0.95	$	(0.34)
Earnings (loss) per share - Diluted:
Continuing operations	$	0.91	$	(0.32)	$	0.94	$	(0.31)
Discontinued operations	$	—	$	(0.01)	$	—	$	(0.03)
Net income (loss)	$	0.91	$	(0.33)	$	0.94	$	(0.34)
Weighted average shares used to compute net loss per share attributable to common shareholders:
Basic	48,866,822		47,798,146		48,663,807		47,468,266
Diluted	49,294,679		47,798,146		49,259,528		47,468,266


			Page 6

BIOLIFE SOLUTIONS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)